Clinical Trial Update: RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors [Phase 1]

View source ↗

Summary

This Phase 1 trial update indicates termination of the pediatric study evaluating RRx-001 with irinotecan and temozolomide for recurrent or progressive malignan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Tumor
• Central Nervous System Neoplasms

Drugs mentioned

• Irinotecan (Irinotecan)
• RRx-001
• Temozolomide (Temozolomide)

Snippet

Sponsor: EpicentRx, Inc. | Conditions: Brain Tumor, Recurrent, Brain Tumor, Pediatric | Phase 1 | Status: TERMINATED